The interaction between RUNX2 and core binding factor beta as a potential therapeutic target in canine osteosarcoma

Veterinary and Comparative Oncology
Fernando AlegreLuke A Wittenburg

Abstract

Osteosarcoma remains the most common primary bone tumour in dogs with half of affected dogs unable to survive 1 year beyond diagnosis. New therapeutic options are needed to improve outcomes for this disease. Recent investigations into potential therapeutic targets have focused on cell surface molecules with little clear therapeutic benefit. Transcription factors and protein interactions represent underdeveloped areas of therapeutic drug development. We have utilized allosteric inhibitors of the core binding factor transcriptional complex, comprised of core binding factor beta (CBFβ) and RUNX2, in four canine osteosarcoma cell lines Active inhibitor compounds demonstrate anti-tumour activities with concentrations demonstrated to be achievable in vivo while an inactive, structural analogue has no activity. We show that CBFβ inhibitors are capable of inducing apoptosis, inhibiting clonogenic cell growth, altering cell cycle progression and impeding migration and invasion in a cell line-dependent manner. These effects coincide with a reduced interaction between RUNX2 and CBFβ and alterations in expression of RUNX2 target genes. We also show that addition of CBFβ inhibitors to the commonly used cytotoxic chemotherapeutic drugs doxor...Continue Reading

References

Dec 16, 1993·Nature·Y XiongD Beach
Jul 18, 2006·Analytical Biochemistry·Bas BrinkhofLouis C Penning
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Aug 4, 2009·Cell and Tissue Research·Toshihisa Komori
Jul 8, 2010·Journal of Cellular Physiology·J Nathan DavisShari Meyers
Apr 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G GrignaniM Aglietta
Oct 2, 2012·The New England Journal of Medicine·Sunil VermaUNKNOWN EMILIA Study Group
Oct 17, 2014·Nature Reviews. Cancer·Maya KansaraDavid M Thomas
Jan 3, 2015·DNA and Cell Biology·Daniel WysokinskiJanusz Blasiak
Jan 15, 2015·The Veterinary Journal·Lorella Maniscalco
Jun 11, 2015·Journal of Cellular Physiology·Na-Rae ParkJe-Yong Choi
Nov 4, 2015·Annual Review of Pharmacology and Toxicology·John S Lazo, Elizabeth R Sharlow
Nov 4, 2015·British Journal of Cancer·Alison RoosJason T Yustein
Dec 3, 2015·Current Opinion in Pediatrics·Michael W BishopRichard Gorlick
Jun 30, 2016·Drug Discovery Today·Hanneke I VosDunja Maroeska W M Te Loo
Jul 20, 2016·EBioMedicine·Anuradha IllendulaJohn H Bushweller
Jan 15, 2017·Cancer Treatment Reviews·Kim C AaldersFatima Cardoso
Dec 7, 2017·Expert Review of Anticancer Therapy·Douglas J HarrisonRichard Gorlick
Jun 21, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Mélanie LambertMarie-Hélène David-Cordonnier

❮ Previous
Next ❯

Citations

Mar 25, 2021·Cancer Management and Research·Weizhu ZhaoLigang Xing

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis